Johnson & Johnson has announced findings from the Phase 3b APEX study demonstrating the efficacy of TREMFYA® (guselkumab) in treating active psoriatic arthritis. The study results, presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, show that TREMFYA® significantly reduced signs and symptoms of the disease and inhibited the progression of joint structural damage at 24 weeks compared to placebo. More than 40% of patients treated with TREMFYA® achieved ACR50, a measure of improvement in joint symptoms, by Week 24. Additionally, a higher proportion of TREMFYA®-treated patients achieved clear or almost clear skin compared to those receiving placebo. The safety profile of TREMFYA® remains consistent with previous studies, with no new safety signals identified.